A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.

Additionally, although patients in this study were not stratified by prior VEGF-targeted therapy and there were more patients who had received prior VEGF-targeted therapy in the LEN18 arm (32.5%) compared to the LEN24 arm (18.7%), a subgroup analysis indicated that LEN24 may result in improved ORR irrespective of prior VEGF-targeted treatment, although this did not reach statistical significance ( Fig. 2 ).

also in 111,027 other papers